A Randomized, Parallel, Double-blind, Placebo-controlled Study of Vitamin D as Prophylactic Treatment for Migraine
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 48
- Locations
- 2
- Primary Endpoint
- The number of migraine attacks
Study Overview
Brief Summary
The trial is primarily designed to investigate whether treatment with vitamin D may influence migraine in a placebo-controlled, blinded study. The hypothesis is that vitamin D may serve as a prophylactic treatment of migraine. The hypothesis is tested by examining the changes in the pain and symptom patterns associated with migraine by treatment with Vitamin D, by means of quantitative sensory testing, diaries and blood samples for measurement of vitamin D. Other pain biomarkers are also measured to evaluate whether the levels of these biomarkers in the blood is changed by the treatment with vitamin D. The hypothesis here is that levels of those biomarkers will change following the treatment.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Men and women between 18 and 65, migraine must have occurred before the age of 50 years.
- •Diagnosed migraine according to International Headache Society (IHS) criteria (ICHD-II)
Exclusion Criteria
- •Other neurological or neurodegenerative disorders
- •Medical conditions that may interfere with the result - violent head trauma, stroke, transient ischemic attacks
- •Musculoskeletal or mental illness
- •Addictive or previous addictive behavior defined as the abuse of cannabis, opioids or other drugs
- •Inability to cooperate
- •Pregnancy or breastfeeding, including women trying to conceive
- •Use of vitamin D supplementation> 10μg
- •In treatment with digoxin or thiazide
- •Patients with osteoarthritis, as they are taking or have taken vitamin D supplements
- •Patients with pre-existing hypercalcemia as vitamin D supplements are contraindicated in these patients
Arms & Interventions
Vitamin D
The active treatment consists of vitamin D and is given in tablets of the brand D3 Vitamin ®, supplied by D3 Pharmacy Ltd., Bispensgade 22, 9000 Aalborg.
The tablets contain the vitamin D in the form of vitamin D3, also known as cholecalciferol.
D3 Vitamin ® consists of small white tablets, which are easy to swallow.
D3 Vitamin ® contains 25 micrograms vitamin D3 (colecalciferol) per tablet, equivalent to 1000 IU (International Units).
Tablet Excipients: Cellulose, dicalcium phosphate, magnesium stearate, silicon dioxide and talc. Vitamin D3 ® contains no gluten, soy, gelatin or other animal products.
Intervention: D3 Vitamin ® (Drug)
Placebo
Placebo tablets to match D3 Vitamin ®, were produced. They are identical to the D3 Vitamin ® in appearance, ie small white tablets. These tablets do not have a therapeutic effect. Placebo tablets produced and delivered by D3 Pharmacy Ltd., Bispensgade 22, 9000 Aalborg.
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
The number of migraine attacks
Time Frame: every 4 weeks
The primary endpoint is the frequency of migraine attacks. This is estimated from the subjects' listing of attacks in the form of diaries. This is assessed as the number of migraine attacks per 4 weeks (28 days).
Secondary Outcomes
- Quantitative Sensory Testing(Every 4 weeks)
- Measuring levels of a biomarker. Changes in the levels of these biomarkers.(Baseline and after 6 months treatment (end of trial))
- Migraine Symptoms(every 4 weeks)
- Hypersensitivity(Baseline and every 4 weeks)
- Evaluation of pain during migraine attacks(every 4 weeks)
Investigators
Parisa Gazerani
Associate Professor, Pharm D, PhD
Aalborg University